“There are women who, for no known reason, have reduced sexual desire that causes marked distress” Hylton V. Joffe “We are incredibly excited with the FDA’s decision to approve the NDA for Vyleesi as a treatment for premenopausal women with HSDD,” said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin.  “This FDA approval